Lieff, Cabraser, Heimann & Bernstein, LLP reminds investors of the September 9, 2013 deadline to move for appointment as lead plaintiff in the
securities class litigation brought on behalf of all persons who purchased or otherwise acquired the shares of LinnCo, LLC (“LinnCo” or the “Company”) (NasdaqGS: LNCO) in or traceable to LinnCo’s initial public offering (“IPO”) on October 12, 2012
If you purchased or otherwise acquired the shares of LinnCo in or traceable to the IPO, you may move the Court for appointment as lead plaintiff by no later than September 9, 2013. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the action will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.
LinnCo investors who wish to learn more about the action and how to seek appointment as lead plaintiff should
or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.
The complaint charges LinnCo., certain of its officers and directors, and the underwriters of the IPO with violations of the Securities Act of 1933. According to the complaint, LinnCo is a Delaware limited liability company whose sole purpose is to own units representing limited liability company interests in Linn Energy, LLC (“Linn Energy”).
The complaint alleges that the Registration Statement issued in connection with the IPO was false and misleading and failed to disclose material adverse facts concerning LinnCo’s business and financial condition. Specifically, the complaint alleges defendants issued false and/or misleading statements and failed to disclose to investors that Linn Energy was overstating the cash flow available for distribution to Linn Energy unitholders, such as LinnCo by, among other things, excluding the cost of certain hedging transactions from its calculation of “Adjusted EBITDA,” a metric highlighted as important in the IPO Prospectus.